MA26667A1 - Composition a base de proteines hedgehog et procede pour sa preparation - Google Patents

Composition a base de proteines hedgehog et procede pour sa preparation

Info

Publication number
MA26667A1
MA26667A1 MA25714A MA25714A MA26667A1 MA 26667 A1 MA26667 A1 MA 26667A1 MA 25714 A MA25714 A MA 25714A MA 25714 A MA25714 A MA 25714A MA 26667 A1 MA26667 A1 MA 26667A1
Authority
MA
Morocco
Prior art keywords
hedgehog protein
preparation
protein composition
ions
composition
Prior art date
Application number
MA25714A
Other languages
English (en)
Inventor
Papadimitriou Apollon
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP98114851A external-priority patent/EP0987028A1/fr
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA26667A1 publication Critical patent/MA26667A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Detergent Compositions (AREA)
MA25714A 1998-08-07 1999-08-04 Composition a base de proteines hedgehog et procede pour sa preparation MA26667A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP98114851A EP0987028A1 (fr) 1998-08-07 1998-08-07 Compositions pharmaceutiques comprennant des hedgehog-proteines et leur utilisation
EP98116734 1998-09-03

Publications (1)

Publication Number Publication Date
MA26667A1 true MA26667A1 (fr) 2004-12-20

Family

ID=26149508

Family Applications (1)

Application Number Title Priority Date Filing Date
MA25714A MA26667A1 (fr) 1998-08-07 1999-08-04 Composition a base de proteines hedgehog et procede pour sa preparation

Country Status (14)

Country Link
US (1) US6207718B1 (fr)
EP (1) EP0978285B1 (fr)
JP (1) JP3567103B2 (fr)
CN (1) CN1244429A (fr)
AT (1) ATE310531T1 (fr)
AU (1) AU761341B2 (fr)
CA (1) CA2279743C (fr)
DE (1) DE69928472T2 (fr)
DK (1) DK0978285T3 (fr)
ES (1) ES2253851T3 (fr)
HU (1) HUP9902655A3 (fr)
IL (1) IL131238A (fr)
MA (1) MA26667A1 (fr)
NO (1) NO993804L (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999028454A1 (fr) * 1997-11-28 1999-06-10 Roche Diagnostics Gmbh Mutant actif de proteine du herisson, son procede de preparation et son utilisation a des fins pharmaceutiques
US6897297B1 (en) * 1997-12-03 2005-05-24 Curis, Inc. Hydrophobically-modified protein compositions and methods
ES2252886T3 (es) * 1998-04-30 2006-05-16 Curis, Inc. Conjugado de proteinas de erizo activo, proceso para su produccion y uso.
EP1025861A1 (fr) * 1999-02-04 2000-08-09 Roche Diagnostics GmbH Compositions pharmaceutiques des Proteines Hedgehog rendues hydrophobes, et leur utilisation
US20040220103A1 (en) * 1999-04-19 2004-11-04 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
CA2280925A1 (fr) * 1999-07-29 2001-01-29 Bernard Charles Sherman Cefuroxime axetil stabilise
WO2001082994A1 (fr) * 2000-04-28 2001-11-08 Curis, Inc. Methodes et reactifs d'elaboration de cartilages in vitro
EP1947116B1 (fr) 2003-02-10 2017-06-21 2-BBB Medicines B.V. Acides nucléiques exprimés par action différentielle dans la barrière hématoencéphalique sous des conditions inflammatoires
WO2004087870A2 (fr) * 2003-03-25 2004-10-14 The Johns Hopkins University Lignees cellulaires neuronales et leurs procedes de production
US20070148144A1 (en) * 2005-10-27 2007-06-28 Mason James M Gene-enhanced tissue engineering
AU2007234612B2 (en) * 2006-12-14 2013-06-27 Johnson & Johnson Regenerative Therapeutics, Llc Protein stabilization formulations
PL2308514T3 (pl) 2007-03-23 2013-11-29 To Bbb Holding B V Koniugaty do ukierunkowanego dostarczania leku poprzez barierę krew-mózg
US7678764B2 (en) * 2007-06-29 2010-03-16 Johnson & Johnson Regenerative Therapeutics, Llc Protein formulations for use at elevated temperatures
DE602008004351D1 (de) * 2007-06-29 2011-02-17 Atrm Llc Flüssige proteinformulierungen mit gdf-5 zur verwendung bei erhöhten temperaturen
JP5323832B2 (ja) * 2007-08-07 2013-10-23 アドバンスト・テクノロジーズ・アンド・リジェネレイティブ・メディスン・エルエルシー 酸性水溶液中にｇｄｆ−５を含むタンパク質製剤
BRPI0911048A2 (pt) * 2008-04-14 2015-12-29 Atrm Llc formulações líquidas tamponadas de gdf-5
WO2010087702A1 (fr) 2009-01-30 2010-08-05 Stichting Katholieke Universiteit Gène tet2 en tant que marqueur pour diagnostiquer un syndrome myélodysplasique (mds) ou une leucémie myéloïde aiguë (aml) et déterminer le pronostic chez un sujet
WO2011034421A1 (fr) 2009-09-16 2011-03-24 Stichting Het Nederlands Kanker Instituut Gènes cibles fra-1 utilisés comme cibles médicamenteuses pour le traitement du cancer
EP2305717A1 (fr) 2009-09-21 2011-04-06 Koninklijke Nederlandse Akademie van Wetenschappen Inhibition du TNIK pour le traitement du cancer du côlon
US9295720B2 (en) 2010-08-27 2016-03-29 Pantarhei Bioscience B.V. Immunotherapeutic method for treating prostate cancer
EP2465928A1 (fr) 2010-12-16 2012-06-20 Academisch Medisch Centrum bij de Universiteit van Amsterdam Traitement des maladies liées au Th17
WO2015070031A1 (fr) 2013-11-08 2015-05-14 University Of Virginia Patent Foundation Compositions et méthodes de traitement du mélanome
WO2016080830A2 (fr) 2014-11-18 2016-05-26 Pantarhei Bioscience B.V. Procédé immunothérapeutique pour le traitement du cancer du pancréas
US12570981B2 (en) 2016-03-21 2026-03-10 University Of Virginia Patent Foundation Genetically modified mouse with conditional deletion of LRP1 in oligodendrocytes
AU2017363131B2 (en) * 2016-11-16 2020-01-16 Aivita Biomedical, Inc. Use of cell membrane-bound signaling factors
CA3082896A1 (fr) * 2017-11-16 2019-05-23 Aivita Biomedical, Inc. Utilisation de facteurs de signalisation lies a une membrane cellulaire
WO2025263459A1 (fr) * 2024-06-17 2025-12-26 学校法人神戸薬科大学 Composition biopharmaceutique

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2148901A (en) 1983-10-04 1985-06-05 Johnson & Johnson Protein/polysaccharide complexes
JPH0725689B2 (ja) 1986-10-07 1995-03-22 中外製薬株式会社 顆粒球コロニ−刺激因子を含有する徐放性製剤
US5078997A (en) 1988-07-13 1992-01-07 Cetus Corporation Pharmaceutical composition for interleukin-2 containing physiologically compatible stabilizers
US5007790A (en) 1989-04-11 1991-04-16 Depomed Systems, Inc. Sustained-release oral drug dosage form
US5156623A (en) 1990-04-16 1992-10-20 Olympus Optical Co., Ltd. Sustained release material and method of manufacturing the same
US5416071A (en) 1991-03-12 1995-05-16 Takeda Chemical Industries, Ltd. Water-soluble composition for sustained-release containing epo and hyaluronic acid
DE4126983A1 (de) 1991-08-15 1993-02-18 Boehringer Mannheim Gmbh Verfahren zur herstellung von humanprotein-enthaltenden, konservierten arzneimitteln fuer infusions- oder injektionszwecke
US5215758A (en) 1991-09-11 1993-06-01 Euroceltique, S.A. Controlled release matrix suppository for pharmaceuticals
US5789543A (en) 1993-12-30 1998-08-04 President And Fellows Of Harvard College Vertebrate embryonic pattern-inducing proteins and uses related thereto
EP0741783B1 (fr) 1993-12-30 2009-03-18 President And Fellows Of Harvard College Proteines de type "hedgehog" induisant une structure embryonnaire chez les vertebres
JPH09509574A (ja) 1994-02-25 1997-09-30 ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨーク 脊索によって発現されるヘッジホッグ、Ｖｈｈ−１、の脊椎動物相同体をコードするＤＮＡ、及びこれらの使用
US5663390A (en) 1996-08-29 1997-09-02 Libbey-Owens-Ford Co. Method of producing organo indium chlorides
JPH10194987A (ja) * 1997-01-14 1998-07-28 Youtai Iwamoto 骨・軟骨形成用組成物
US6656508B2 (en) 1997-04-17 2003-12-02 Amgen Inc. Sustained-release alginate gels
EP0947201B1 (fr) * 1998-02-04 2006-06-28 Curis, Inc. Compositions pharmaceutiques contenant des protéines Hedgehog, et leur utilisation
EP0953575A1 (fr) * 1998-04-30 1999-11-03 Boehringer Mannheim Gmbh Conjugué de proteine hedgehog active, procédé pour sa production et utilisation
ES2252886T3 (es) * 1998-04-30 2006-05-16 Curis, Inc. Conjugado de proteinas de erizo activo, proceso para su produccion y uso.

Also Published As

Publication number Publication date
EP0978285A1 (fr) 2000-02-09
US6207718B1 (en) 2001-03-27
IL131238A (en) 2005-07-25
EP0978285B1 (fr) 2005-11-23
CA2279743C (fr) 2005-05-10
CN1244429A (zh) 2000-02-16
NO993804L (no) 2000-02-08
ATE310531T1 (de) 2005-12-15
JP2000063283A (ja) 2000-02-29
DE69928472D1 (de) 2005-12-29
HK1025740A1 (en) 2000-11-24
CA2279743A1 (fr) 2000-02-07
IL131238A0 (en) 2001-01-28
JP3567103B2 (ja) 2004-09-22
HU9902655D0 (en) 1999-10-28
HUP9902655A2 (hu) 2000-08-28
HUP9902655A3 (en) 2000-12-28
ES2253851T3 (es) 2006-06-01
NO993804D0 (no) 1999-08-06
DK0978285T3 (da) 2006-03-27
AU761341B2 (en) 2003-06-05
DE69928472T2 (de) 2006-08-10
AU4344899A (en) 2000-03-02

Similar Documents

Publication Publication Date Title
MA26667A1 (fr) Composition a base de proteines hedgehog et procede pour sa preparation
MA25009A1 (fr) Procede de preparation de composes derives de la piperidine pour la preparation de compositions antibacteriennes
CA2316358A1 (fr) Composition de blanchiment au chlore acide stabilisee et procede d'utilisation
IT1306180B1 (it) Battericida contenente ioni ferro.
BRPI9910332B8 (pt) método para purificação de um polipeptídio a partir de uma composição
ATE250431T1 (de) Verbesserte zusammensetzungen mit unkomplexiertem cyclodextrin zur geruchskontrolle
EP1106061A4 (fr) Procede de modification des chromosomes
MA26782A1 (fr) Pyrazolobenzodiazepines en tant qu'inhibiteurs de cdk2.
ES2100500T3 (es) Compuesto que mejora las propiedades reologicas de productos a base de cemento.
AU2002229094A1 (en) Methods, compositions, articles for control of malodor
EP1112248A4 (fr) Procede permettant de produire des compositions tensioactives
MX9202413A (es) Composiciones acuosas de citrato de calcio.
BR0009502A (pt) Componente de amaciamento de tecido
FR2832399B1 (fr) Procede de preparation de ferrates de metaux alcalins et nouveaux granules de ferrates de metaux alcalins
BR0009470A (pt) Tablete detergente perfumado
BR0009469A (pt) Tablete perfumado de detergente
DE59806013D1 (de) Aktivchlorabspaltender Toilettenreinigungsblock
FR2452921A1 (fr) Procede d'obtention de compositions parfumantes et de produits parfumes et compositions et produits ainsi obtenus
DE69521310D1 (de) Chinolonderivat zur behandlung der harnincontinenz
FR2740450B1 (fr) Procede d'obtention de compositions parfumantes et de produits parfumes et produits ainsi obtenus
DZ2770A1 (fr) Procédé de préparation de 1h-indol-3 glyoxamides substituées en position 4.
FR2721508B1 (fr) Procédé d'obtention de compositions parfumantes et de produits parfumés et produits ainsi obtenus.
EP1295864A4 (fr) Procede de preparation de 1,5-diaminonaphtalenes
TR199901897A2 (xx) İspençiyari kirpi proteinleri terkibi ve bunun kullanılması.
FR2779740B1 (fr) Procede d'obtention d'amidon modifie